Ciclesonide shows a lung-protective effect in neonatal hyperoxia-exposed rats

Area of Science:

• Neonatal Medicine
• Pulmonology
• Pharmacology

Background:

• Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants caused by lung injury and impaired repair.
• Current postnatal corticosteroid treatments for BPD have risks and limited efficacy.
• Identifying safer alternatives for BPD treatment is crucial.

Purpose of the Study:

• To evaluate ciclesonide, an alternative glucocorticoid, for treating BPD.
• To assess ciclesonide's effect on lung structure and right ventricular hypertrophy in a hyperoxic rat model.

Main Methods:

• A hyperoxia-induced BPD-like model was used in rat pups.
• Ciclesonide was administered subcutaneously for 5 days postnatally.
• Lung function, structure, and right ventricular hypertrophy were assessed on postnatal day 14.

Main Results:

• Hyperoxia exposure impaired lung compliance, structure, and caused right ventricular hypertrophy.
• Ciclesonide treatment improved lung compliance and alveolarization.
• Ciclesonide also enhanced lung vascular growth and reduced right ventricular hypertrophy.

Conclusions:

• Postnatal ciclesonide preserved lung function and structure in a hyperoxic BPD model.
• Ciclesonide prevented right ventricular hypertrophy, indicating potential therapeutic benefits.
• Further long-term studies are needed to confirm ciclesonide as a BPD treatment alternative.